OPEN ACCESS Freely available online

ISSN: 2329-6887
Journal of Pharmacovigilance

Perspective

Therapeutic Drug Monitoring in Clinical Setting

Alexandre Bagheri*

Department of Medicine, University of Montreal, Montreal, Canada

DESCRIPTION

Therapeutic Drug Monitoring (TDM) is a subfield of medical applications and clinical toxicology that focuses on determining medication concentrations in the blood. Its primary focus focuses on medications with a restricted therapeutic range, or those that are readily under- or overdosed. TDM intended to improve patient care by individually changing the dose of medications that have shown to improve outcomes in general or special groups in clinical experience or clinical trials. It can be based on a priori pharmacogenetic, demographic and clinical data, as well as a posteriori measurements of drug concentrations in the blood, biological surrogates, or effect end-point markers (pharmacodynamics monitoring). There seem to be innumerable aspects that affect the explanation of drug analysis of samples: duration, path and dosages of drug given, time of blood collection, storage and handling circumstances, precision and accuracy of the analysis approach, truthfulness of pharmacokinetic models and assumptions, co-medications and, steadily for the past but not slightest, diagnostic status of the patient. The numerous parts of drug concentration monitoring, which is a true interdisciplinary procedure, involve many different experts (physicians, clinical pharmacists, nurses, medical laboratory scientists, and so on). A systematic approach to the complete procedure is crucial since failing to effectively carry out just one of the components can have a significant impact on the usefulness of using medication concentrations to optimize therapy.

Therapeutic drug monitoring is a professional procedure that involves measuring certain medications at predetermined intervals in order to maintain a consistent concentration in a patient's circulation, allowing customized dosing regimens to be optimized. The majority of pharmaceuticals do not require TDM, and it is only used to monitor drugs with limited therapeutic ranges, drugs with high pharmacokinetic variability, medications with difficult target concentrations to monitor, and drugs with documented therapeutic and adverse effects. TDM is based on the notion that there is a defined link between dose and drug concentration in the plasma or blood, as well as between concentration and therapeutic effects. TDM starts with the initial prescription of the drug and includes defining an initial dosage regimen that is appropriate for the clinical condition as well as patient variables such as gender, bodyweight, body functions, and concomitant pharmacological therapy. The sample period in relation to the medication dose, dosing history, patient reaction, and the planned medical targets are all elements to consider when interpreting concentration values. TDM aims to optimize therapeutic outcomes in patients in a variety of clinical circumstances by using optimal doses of difficult-to-manage drugs.

Therapeutic drug monitoring is especially beneficial for medicines with a limited therapeutic window. A drug's therapeutic index (therapeutic ratio, toxic-therapeutic ratio) reveals the difference between the acute toxicity levels - the greater the percentage, the healthier. Penicillin has a very high therapeutic ratio for most patients (excluding people who are truly allergic), and it is safe to use in many higher doses than those required to treat the patient, with no need to check the concentration achieved. However, the difference between desired and hazardous doses for other medications (such as immunosuppressive, anticoagulants, aminoglycoside antibiotics, and cardiac glycosides) is very tiny, and some type of monitoring is required to achieve maximum efficacy with minimal toxicity.

Therapeutic drug monitoring is necessary for just a tiny percentage of medications used in drug therapy, yet it is critical for these drugs to achieve optimum efficacy while avoiding drug toxicity. Therapeutic drug monitoring can also help us avoid unpleasant side effects. Due to new developments in information technology, new analytical procedures for less frequently monitored drugs, and new clinical pharmacological expert opinions in the presentation of laboratory medicine results, the old approach to therapeutic drug monitoring for avoiding drug toxicity needs to be revised at this time. Instead than establishing the cause of a current adverse medication response, therapeutic drug monitoring can now be used to prevent one. If the patient is not considered to be part of the normal patient population, blood should be drawn for therapeutic drug monitoring after the pharmacokinetic steadystate has been reached (five times the drug's elimination half-life) after administration of low to moderate dosage under the intended poly-medication. Therapeutic drug monitoring has numerous advantages, including significant cost savings due to the patient's shorter stay in the hospital and the avoidance of costly diagnosis and treatment of an adverse medication event.

Correspondence to: Alexandre Bagheri, Department of Medicine, University of Montreal, Montreal, Canada, E-mail: bagheri.alexandre@chu.ca

Received: 09-Mar-2022, Manuscript No. JP-22-16591; **Editor assigned:** 14-Mar-2022, PreQC No. JP-22-16591 (PQ); **Reviewed:** 28-Mar-2022, QC No.JP-22-16591; **Revised:** 04-Apr-2022, Manuscript No. JP-22-16591 (R); **Published:** 11-Apr-2022, DOI: 10.35248/2329-6887.22.10.366.

Citation: Bagheri A (2022) Therapeutic Drug Monitoring in Clinical Setting. J Pharmacovigil. 10:366.